|
| 37922438 | Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591. | J Clin Oncol | 2024 |
| 36376168 | Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective Experience. | Clin Genitourin Cancer | 2023 |
| 37562861 | Severe hypercalcaemia in metastatic prostate cancer with biallelic BRCA2 mutations and lytic bone lesions. | BMJ Case Rep | 2023 |
| 37589230 | Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer. | Oncologist | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37018944 | Case report: Robotic lymph node resection off the aortic bifurcation for presumed recurrence management of advanced ovarian cancer. | Int J Surg Case Rep | 2023 |
| 37251627 | Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. | EClinicalMedicine | 2023 |
| 37113064 | Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide. | Prostate | 2023 |
| 37467457 | Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. | JCO Precis Oncol | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37265409 | Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer. | Clin Cancer Res | 2023 |
| 37032186 | Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. | Eur Urol | 2023 |
| 36959766 | Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. | Prostate | 2023 |
| 36924989 | Next generation radiotheranostics promoting precision medicine. | Ann Oncol | 2023 |
| 36806966 | PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. | Oncologist | 2023 |
| 36912567 | Localized Prostate Cancer - Then and Now. | N Engl J Med | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36895851 | Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. | Ther Adv Med Oncol | 2023 |
| 36210487 | Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab. | Oncologist | 2023 |
| 36302656 | Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study. | J Nucl Med | 2023 |
| 36200788 | The Value of Phenotypic Precision Medicine in Prostate Cancer. | Oncologist | 2023 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 36321991 | Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 34168015 | <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. | J Nucl Med | 2022 |
| 35652618 | The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. | Prostate | 2022 |
| 35478055 | Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. | Med Oncol | 2022 |
| 35677318 | Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. | Ther Adv Med Oncol | 2022 |
| 35675855 | The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. | Int J Radiat Oncol Biol Phys | 2022 |
| 35649665 | Prostate Cancer Treatment: <sup>177</sup>Lu-PSMA-617 Considerations, Concepts, and Limitations. | J Nucl Med | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35439030 | Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? | J Clin Oncol | 2022 |
| 35697600 | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy. | Eur Urol Oncol | 2022 |
| 35569466 | The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. | Lancet | 2022 |
| 35392296 | Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer. | Cancer Inform | 2022 |
| 35717044 | Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177. | Pract Radiat Oncol | 2022 |
| 35389387 | Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. | Clin Adv Hematol Oncol | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35618477 | Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA: A Multicenter Retrospective Analysis. | J Nucl Med | 2022 |
| 36561718 | Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts. | Front Med (Lausanne) | 2022 |
| 36524004 | Editorial: Prostate cancer genomics: Application at different stages of a patient's journey. | Front Oncol | 2022 |
| 35869001 | Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 36261051 | Predicting benefit from [<sup>177</sup>Lu]Lu-PSMA-617 therapy: what do we need to know? | Lancet Oncol | 2022 |
| 36116477 | The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. | Lancet | 2022 |
| 36185208 | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. | Front Oncol | 2022 |
| 35254710 | Immune mechanisms behind prostate cancer in men of African ancestry: A review. | Prostate | 2022 |
| 35190653 | Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). | Prostate Cancer Prostatic Dis | 2022 |
| 34918105 | Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart. | J Mol Cell Biol | 2022 |
| 35274720 | Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. | Oncologist | 2022 |
| 34863587 | Inherited TP53 Variants and Risk of Prostate Cancer. | Eur Urol | 2022 |